TransMedics Group (NASDAQ:TMDX) Stock Price Down 4.9% - Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares dropped 4.9% during mid-day trading on Wednesday . The stock traded as low as $125.52 and last traded at $129.51. Approximately 418,244 shares traded hands during trading, a decline of 69% from the average daily volume of 1,357,738 shares. The stock had previously closed at $136.20.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Tuesday. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Piper Sandler reissued an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Oppenheimer lifted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus price target of $127.33.

TransMedics Group Stock Down 7.7%

The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of 91.92 and a beta of 2.10. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. The business's 50 day moving average is $111.44 and its 200-day moving average is $83.14.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The company had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. During the same period last year, the business posted $0.35 earnings per share. The firm's revenue was up 48.2% compared to the same quarter last year. Equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the transaction, the director now directly owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director now directly owns 12,134 shares in the company, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,418 shares of company stock worth $1,512,613 over the last three months. Company insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently modified their holdings of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in TransMedics Group by 244.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after acquiring an additional 2,209,996 shares during the period. Braidwell LP acquired a new stake in shares of TransMedics Group during the fourth quarter worth $57,493,000. Norges Bank bought a new stake in TransMedics Group in the fourth quarter valued at about $22,861,000. Mackenzie Financial Corp lifted its stake in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after buying an additional 349,403 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.